Compare Summit Therapeutics Inc (SMMT) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs TORM plc — how do they compare? Summit Therapeutics Inc trades at $15.24 (market cap $12.06B), while TORM plc trades at $28.86 (market cap $2.93B). The key difference: Summit Therapeutics Inc is far larger — about 4.1× TORM plc's market cap, and TORM plc pays a 9.77% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TRMD | |
|---|---|---|
Market Cap | $12.06B | $2.93B |
Sector | Health | Technology |
52-Week High | $26.98 | $34.87 |
52-Week Low | $12.55 | $18.77 |
Enterprise Value | $11.39B | $3.82B |
Dividend Yield | — | 9.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
TRMD trades at $29.04, down 0.51% today, with a bearish technical signal from moving averages but oversold RSI at 24.63. The company reported strong profitability with a 24.41% net margin and ROE of 15.62%, though Q1 2026 EPS missed expectations. Recent news highlights a major shareholder update from Oaktree Capital and a $0.70 dividend payment scheduled for June 2026.
Outlook remains positive with 100% analyst buy ratings, underpinned by robust cash flow and strategic positioning in tanker markets. Risks include earnings volatility and geopolitical impacts on freight rates, but valuation metrics like P/E of 8.4 suggest potential upside if operational execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
